Weekly Research Analysts’ Ratings Changes for Parabilis Medicines (PBLS)

Parabilis Medicines (NASDAQ: PBLS) recently received a number of ratings updates from brokerages and research firms:

• 7/7/2026 – Parabilis Medicines was upgraded by Zacks Research to “hold”.
• 7/6/2026 – Parabilis Medicines is now covered by Guggenheim. They set a “buy” rating and a $40.00 price target on the stock.
• 7/6/2026 – Parabilis Medicines was upgraded by Lifesci Capital to “strong-buy”.
• 7/6/2026 – Parabilis Medicines is now covered by Guggenheim. They set a “buy” rating and a $40.00 price target on the stock.
• 7/6/2026 – Parabilis Medicines is now covered by Evercore Inc. They set an “outperform” rating on the stock.
• 7/6/2026 – Parabilis Medicines is now covered by Bank of America Corporation. They set a “buy” rating and a $45.00 price target on the stock.
• 7/6/2026 – Parabilis Medicines is now covered by Leerink Partners. They set an “outperform” rating and a $40.00 price target on the stock.
• 6/20/2026 – Parabilis Medicines was upgraded by Wall Street Zen to “hold”.

Insider Transactions at Parabilis Medicines

In related news, Director Alan Sebulsky bought 9,065 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average cost of $26.49 per share, with a total value of $240,131.85. Following the completion of the acquisition, the director directly owned 30,000 shares in the company, valued at approximately $794,700. The trade was a 43.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Guy Levy purchased 500,000 shares of Parabilis Medicines stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average price of $20.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the insider owned 1,027,000 shares of the company’s stock, valued at $20,540,000. This represents a 94.88% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 530,000 shares of company stock worth $10,723,528 in the last 90 days.